share_log

HC Wainwright & Co. Maintains Neutral on Fate Therapeutics, Lowers Price Target to $5

Benzinga ·  May 16 19:39

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target from $7 to $5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment